Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncol
ST. LOUIS & SAN DIEGO--(BUSINESS WIRE)--Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced it will present preclinical data on WU-NK-101, the company’s lead memory natural killer...
Source: pharmiweb.com
